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DOI: 10.1039/c1lc20298gEarly development drug formulation is exacerbated by increasingly poor bioavailability of potential
candidates. Prevention of attrition due to formulation problems necessitates physicochemical analysis
and formulation studies at a very early stage during development, where the availability of a new
substance is limited to small quantities, thus impeding extensive experiments. Miniaturization of
common formulation processes is a strategy to overcome those limitations. We present a versatile
technique for fabricating drug nanoformulations using a microfluidic spray dryer. Nanoparticles are
formed by evaporative precipitation of the drug-loaded spray in air at room temperature. Using
danazol as a model drug, amorphous nanoparticles of 20–60 nm in diameter are prepared with
a narrow size distribution. We design the device with a geometry that allows the injection of two
separate solvent streams, thus enabling co-spray drying of two substances for the production of drug
co-precipitates with tailor-made composition for optimization of therapeutic efficiency.Introduction
The development of novel pharmaceuticals is a challenging field
involving cost-intensive research in combination with a high
attrition rate of potential candidates.1,2 Due to high-throughput
technologies an increasing number of new chemical entities with
potential therapeutic efficiency is identified.3,4 Unfortunately, the
molecular complexity of drugs has significantly increased over
the last decade.5–7 Although molecular complexity usually
contributes to biological activity, it often causes poor solubility
of drugs.6,8 This limits their bioavailability in the human body,
and the reason for attrition of pharmacologically promising
substances can often be found in the failure to develop a suitable
formulation for therapeutic application.9 Prevention of failure
due to formulation limitations necessitates physicochemical
analysis and formulation studies at a very early stage during
development.10,11 At this stage, the availability of the drug
candidate is limited to small amounts, thus hampering extensive
experiments.
One suitable approach to increase the bioavailability of a drug
is to reduce the particle size, which increases the specific surfaceaSchool of Engineering and Applied Sciences, Department of Physics,
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2362 | Lab Chip, 2011, 11, 2362–2368and, therefore, facilitates release and absorption of the drug.12–15
Furthermore, increased bioavailability can be achieved by
amorphization of the sample. In this context, spray drying is
a powerful technique enabling instantaneous drying of solutions,
emulsions or suspensions in one step. The final product is a fine,
often amorphous powder with a large surface. Pharmaceutical
application of spray drying techniques are ubiquitous; their use
ranges from the manufacture of dry plant extracts for avoiding
decomposition of thermally degradable components, to the
production of excipients for compression with improved binding
characteristics.16–18 Furthermore, the technique is successfully
used for co-precipitation of a drug and another substance to
increase the drug’s bioavailability.19 However unfortunately, in
case of early stage formulation development the use of conven-
tional spray drying setups is restricted. Conventional spray
drying equipment requires large amounts of sample as the dead
volume of the apparatus is rather large and a considerable
portion of discard material is generated during the process.
Furthermore, the optimization of processing parameters neces-
sitates additional quantities of sample to receive a homogeneous
product. Moreover, particle sizes below 100 nm, as often
required for targeted drug delivery, are extremely hard to
generate.20,21 An appropriate application for spray drying for
early development drug formulation would require the minia-
turization of the setup. These limitations can be overcome using
microfluidic techniques.22–26 Extremely small volumes can
precisely be handled on microfluidic chips enabling the
controlled generation of homogeneous products as well as a fast
change of process conditions. It would be highly desirable toThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlinedesign a microfluidic chip which combines the versatility of
microfluidics with the ability to formulate drug particles with
high accuracy using spray drying techniques.
In this paper, we present the first microfluidic spray dryer on
a poly(dimethylsiloxane) (PDMS) chip.27–29 We use the hydro-
phobic model drug danazol to test the new device. By controlling
the collection distance of the spray, we can control the crystal-
linity of the product. Our microfluidic device enables fabrication
of drug nanoparticles with sizes of less than 100 nm in diameter.
The versatile device design also enables the formation of amor-
phous co-precipitates by co-spray drying two substances.
Results and discussion
In conventional spray dryers, a single liquid stream is typically
vaporized by compressed air in a spray nozzle; the spray is then
mixed with a heated gas stream in a drying chamber to evaporate
the solvent and yield the dry product.21 However, this setup only
allows processing of single solvent systems or mixtures of pre-
mixed solvents. To process multiple separate solvent streams as
required for solvent/antisolvent precipitation or rapidly reacting
solvent streams, the spray dryer generally needs to be equipped
with additional separate inlet channels.30 In this work, we use
a microfluidic device with an array of two flow-focusing cross
junctions, as shown in Fig. 1.
The device enables separate injection of two solvents and
provides a third inlet for compressed air to form the spray.
For the formation of hydrophobic drug nanoparticles, we
dissolve the hydrophobic drug danazol in an organic solvent
injected into the first inlet, and inject the second fluid into the
second inlet. The two solvents form a jet at the first cross junc-
tion, which extends into the second cross junction where
compressed air is injected to form the spray. To process hydro-
phobic drugs, the PDMS device must resist fouling due to
adsorption of drug crystals on the microchannel walls.31,32 This is
especially crucial when starting up the device, as potential
backflow of the drug-loaded solvent stream into the anti-solvent
reservoir, and vice versa, can cause significant precipitation of the
hydrophobic drug in the microchannels. To prevent adsorption
of the drug on the microchannel walls, we treat the intrinsically
hydrophobic PDMS device with oxygen plasma, as the plasma
renders the walls of the device hydrophilic.33 Although the
hydrophilicity of the plasma treated device decreases over time,Fig. 1 Schematic of a microfluidic device for forming nanoparticles
from hydrophobic drugs by spray drying. The microfluidic device is
rendered hydrophilic with an oxygen plasma treatment. The device
geometry enables separate injection of two solvent streams of which the
spray is formed.
This journal is ª The Royal Society of Chemistry 2011the channel surface can easily be regenerated in the same manner
multiple times. However, for early development drug formula-
tion, the amount of sample is extremely small thus being the
limiting factor in such an experiment rather than the duration of
a surface plasma treatment. In addition, we minimize the surface
contact between the drug-loaded solvent stream and the channel
walls. We achieve this by designing a device geometry with a high
aspect ratio. The ratio h/w is 10 : 1 in the upper half of the device
and 4 : 1 at the spray nozzle. Although high-aspect-ratio channel
geometries are generally known to increase surface interactions,34
microchannels with a high aspect ratio are less pressure-resistant
than squared channels, when fabricated in the rather soft PDMS;Fig. 2 Pressure-induced deformation of the microfluidic spray dryer
during operation. (A) Bright-field microscopy images of the microfluidic
spray dryer at low pressure (left) and operating pressure (right). The dark
fields in the microchannels indicate the curvature of the channel walls
causing the light to scatter. The scale bars denote 50 mm, scale bars for the
magnified view are 20 mm. (B) The impact of the deformation on the flow
profile is studied using CFD simulations based on the finite element
method. The initial rectangular microchannels (left) expand and adopt
a circular shape (right). This deformation changes the flow pattern from
a two dimensional focused flow to an elliptic to coaxial flow, therefore
reducing the contact between the drug-loaded solvent stream and the
channels walls. To emphasize the deformation, the simulation model is
viewed from an angle of approximately 30 above the second cross
junction, and the original position of the microchannel walls is added as
black lines to the simulation model.
Lab Chip, 2011, 11, 2362–2368 | 2363
Fig. 3 (A) Spray profile of the nozzle for different air pressures. IPA is
injected into the spray dryer at 55 mL h1. At low pressure, a fluid jet is
ejected from the nozzle which breaks into single droplets downstream.
When the pressure is increased beyond 0.5 bar, the spray profile adopts
a cone-like shape. The scale bar for all panels denotes 100 mm. (B) Drop
diameter as a function of p. With increasing pressure, the mean size of the
droplets decreases linearly. At a pressure of 2.09 bar, the droplets are
approximately 4 mm in diameter. The red line is a guide to the eye.
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View Article Onlinethus the operating spray dryer channels easily expand, as shown
in Fig. 2.
To determine the impact of the channel deformation on the
flow profile, we process a typical solvent/antisolvent system in
our spray dryer and compare the device deformation at low and
high flow rates and air pressure, respectively. Our observations
are supported by computational fluid dynamics (CFD) simula-
tions coupled with fluid-structure interaction (FSI) using
COMSOL 4.1.0.185. We design a 3D simulation model of the
microfluidic spray dryer considering the solid mechanics of the
device described by a linear elastic model and the fluid flow
therein described by the Navier–Stokes equations. For the device
building material PDMS, which is mixed from the pre-polymer
and crosslinker in a ratio of 10 : 1, Young’s modulus is
approximately 4 MPa, the Poisson’s Ratio is 0.42, and the
density is 920 kg m3.35,36 The model consists of 62 713 finite
elements with an average mesh quality of 0.8003 on a scale of 0 to
1, where 1 is the highest quality. The model is solved for 401 878
degrees of freedom. A detailed discussion of the simulation
model and its mathematical background is provided in the ESI†
for this publication. For the spray experiment at low flow rates
and low pressure, we inject isopropyl alcohol (IPA) as the
solvent, water as the anti-solvent and compressed air into the
first, second and third inlet, respectively, at flow rates of 1 mL h1
for the inner phase and 10 mL h1 for the middle phase. The air
pressure is set to 0.34 bar. For the high-flow rate/high-pressure
experiment, we increase the flow rates of IPA and water to
5 mL h1 and 50 mL h1, respectively, and set the air pressure to
2.09 bar. At low pressure (0.34 bar), the PDMS device demon-
strates minimal deformation and we observe a two dimensional
focused flow pattern between the first and second cross junction.
However, as we increase the pressure, the PDMS device responds
to the internal stress and expands, as shown in the magnified view
of Fig. 2A. Due to the high aspect ratio, the largest expansion of
the microchannels is observed in the side walls of the channels.
Image analysis of microscope images shows that the micro-
channels widen by an average factor of two, as shown in the
magnified views in Fig. 2A. This deformation strongly influences
the flow profile inside the spray dryer, as shown in the corre-
sponding simulations in Fig. 2B. As illustrated by the slice plot of
the simulated velocity profile, the flow between the first and
second cross junction adopts a three dimensional flow pattern,
similar to that observed in microfluidic capillary devices.37
Thereby, the inner phase is surrounded by a protective sheath of
the middle phase, as shown in the magnified view of Fig. 2A
(right). This minimizes the surface contact of the solvent in which
the hydrophobic drug is dissolved with the channel walls and
prevents fouling of our device.
When forming a spray, the spray shape and drop size are
important factors influencing drying, particle size and
morphology of the processed drug. To determine drop size and
spray shape, we visualize the spray formation in our spray dryer
with a high-speed camera. We inject IPA into the first and second
inlet at a total flow rate of 55 mL h1. At low air pressure, the
solvent stream is not dispersed into a spray; instead, a jet of
liquid is ejected from the spray nozzle and breaks into large
droplets due to Rayleigh-Plateau instability, as shown in
Fig. 3A.37 As the air pressure is increased beyond 0.5 bar, we
observe the formation of a mixture of large drops and finely2364 | Lab Chip, 2011, 11, 2362–2368dispersed drops at the spray nozzle; the onset of spraying can be
confirmed by the round full cone pattern adopted by the droplets
formed, that appears as a triangular spray pattern in the side
view of the high-speed camera. This precise pattern is formed due
to turbulences imparted to the liquid prior to the orifice in the
short outlet channel. To quantify the spray formation process,
we measure the drop size d as a function of the air pressure p, as
shown in Fig. 3B. The drop size decreases linearly with increasing
pressure to approximately 4 mm in diameter at 2.1 bar, which is
the maximum pressure our spray dryer can withstand without
delamination of the plasma-bonded PDMS.
We demonstrate the concept to form hydrophobic drug
nanoparticles with our microfluidic spray dryer. Danazol is used
as a model drug, which is an isoxazole derivative of testosterone
and applied for the treatment of endometriosis and hereditary
angioedema.23 In general, a convenient method for processing
hydrophobic drugs is liquid antisolvent precipitation (LASP),
where the drug, dissolved in an alcohol, is precipitated by mixing
the drug solution with water as the antisolvent.16,38 We dissolve
danazol in isopropyl alcohol and inject it together with water
into the first cross junction. As we operate our microfluidic
device in the laminar flow regime, only diffusion based mixing of
the solvent streams is observed at their interfaces. To evaluate the
effect of microfluidic processing alone on the particle size and
morphology of the hydrophobic drug, no stabilizer or surfactant
is added to influence the particle growth, nor do we use common
co-solvents such as DMSO and benzyl alcohol. We set the flow
rates to 5 mL h1 for danazol, and 50 mL h1 for water, which
corresponds to a volumetric ratio of 1 : 10 and has been shown to
yield danazol microparticles in conventional LASP processes.23This journal is ª The Royal Society of Chemistry 2011
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View Article OnlineThe spray is suspended in air, thus ensuring that the product is
dried upon collection. We examine the morphology and particle
size of the processed drug using scanning electron microscopy
(SEM). While unprocessed danazol is composed of particles with
irregular shapes ranging from approximately 2 mm to 100 mm, the
particle size is reduced significantly by processing the drug using
our microfluidic spray dryer. As shown in Fig. 4A, we yield
danazol nanoparticles with a narrow particle size distribution
(PSD) from 20 nm to 60 nm and, therefore, smaller than previ-
ously reported.7,23
The formation of drug nanoparticles using LASP is driven by
mixing of the drug solution with the antisolvent. Thus, the degree
of supersaturation of the drug solution governs nucleation and
growth of the drug nanoparticles.16 However, sufficient mixing
only occurs in the short outlet channel prior to the orifice of the
spray nozzle in our microfluidic device. Since we use high flow
rates to form a stable spray, the delay time of the fluids in the
outlet channel should be too short to enable growth of the drug
nuclei by mixing. To reveal the formation process, we replace the
antisolvent with the solvent, and inject a solution of danazol in
IPA and pure IPA into the first and second inlet, respectively.
The formation of danazol nanoparticles of identical size and
morphology in the absence of the antisolvent indicates that the
particle formation is primarily driven by the evaporation of the
spray and not by the formation of nuclei due to supersaturation,
as shown in Fig. 4B. Our hypothesis is further supported by using
a microfluidic spray dryer with a longer channel between the first
and second nozzle and thus increased time of diffusion, which
does not have a significant influence on the particle properties.
Another crucial aspect of the spray drying process is the
distance from the spray drying nozzle at which the final product
is collected. While it is known that the morphology and size of
hydrophobic drugs depends on the initial concentration of
reactants, the choice of additives and the ratio of solvent and
antisolvent,39 we find a significant dependence on the collection
distance by performing spatial sampling of the spray. To illus-
trate this, we inject danazol and IPA as described above, but thisFig. 4 Effect of the solvent system on particle size and composition.
Danazol in IPA is mixed with (A) water as the antisolvent, or (B) IPA as
the solvent inside the microfluidic spray dryer. In either case, nano-
particles are produced with a narrow PSD and an average diameter of
20–60 nm. Scale bars denote 300 nm.
This journal is ª The Royal Society of Chemistry 2011time we collect the spray in steps of 5 cm from the spray nozzle.
From our SEM analysis, two distinct product morphologies are
revealed. At a collection distance of 5 cm, we observe an
assembly of stacks of danazol; the thickness of each stack is
about 60–80 nm, as shown in Fig. 5A. These values are in good
agreement with the size of single danazol nanoparticles, as shown
in Fig. 4A and 4B.
However, as the time of flight is too short to allow for complete
evaporation of the spray upon collection, the remaining solvent
increases the mobility of danazol particles on the collection
substrate, allowing them to fuse and reach an energetically more
favorable state.16 We therefore increase the collection distance to
30 cm; as the spray is completely evaporated, single nanoparticles
are formed, that become densely packed over the long time of
sample collection, as shown in Fig. 5B. X-ray powder diffraction
analysis (XRD) is employed to determine the effect of spatial
sampling on the crystallinity of danazol. We use the character-
istic peaks at 2q of 15.8, 17.1 and 19.0 in the XRD pattern of
unprocessed danazol as a reference. In processed danazol, the
intensity of the characteristic peaks decreases as the collection
distance of the spray is increased. This indicates that the initial
crystallinity of the drug is not recovered, as shown in Fig. 5C.
The formation of amorphous danazol is of importance, as the
difference in physicochemical properties of the amorphous form
significantly increases the bioavailability of danazol.23
Another way to fabricate amorphous hydrophobic drug
particles is to co-spray dry the drug and a crystallization inhib-
itor.40 As a control experiment, we first co-spray dry danazol in
IPA together with water and collect the spray at low distance. As
shown before, the spray is not completely evaporated due to the
short time of flight. This allows danazol to grow into star-shape
crystalline aggregates, as shown in Fig. 6A. We use poly(vinyl-
pyrrolidone) (PVP) as a substance for co-spray drying withFig. 5 Spatial sampling of processed danazol. Depending on the
collection distance, various morphologies are observed; (A) assembly of
stacks with a thickness of 60–80 nm, and (B) nanoparticles, approxi-
mately 20 nm to 60 nm in diameter, assembled in a dense network. (C)
XRD patterns of processed danazol collected at a distance of 5 cm and
30 cm from the spray nozzle, and unprocessed danazol as a reference.
Lab Chip, 2011, 11, 2362–2368 | 2365
Fig. 6 Inhibition of danazol crystallization by PVP. (A) Danazol in IPA
is mixed with water inside the microfluidic device; the spray is collected at
a distance of 1 cm from the nozzle, allowing danazol to grow into crys-
talline aggregates, as indicated by the XRD pattern. The scale bar is 5 mm.
(B) By processing danazol in IPA and an aqueous solution of PVP, which
are injected separately into our spray dryer, amorphous co-precipitates
are yielded, as indicated by the corresponding XRD pattern. The scale
bar denotes 500 nm.
Fig. 7 Fabrication of danazol particles and danazol/PVP co-precipitates
in a conventional spray dryer using the same formulations as in our
microfluidic device. (A) Instead of amorphous drug nanoparticles, crys-
talline particles, and (B) microscopic co-precipitates are yielded.
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View Article Onlinedanazol to fabricate amorphous co-precipitates, as PVP is
known to inhibit crystal growth in pharmaceutical formula-
tions.41–44 We process danazol in IPA together with a 1.5 wt%
solution of PVP in water at equal flow rates of 25 mL h1. Again,
the spray is collected at short distance. However, as the spray is
dried, danazol precipitates from the spray in a combination with
PVP without crystallization, thus no characteristic peaks are
observed in the XRD pattern, as shown in Fig. 6B.
To relate the performance of our microfluidic spray dryer to
conventional spray dryers, we perform spray drying experiments
with the same formulations and compare the results by XRD and
SEM. We use the well-established and widely known Mini Spray
Dryer B-191 (Buechi, Germany) with a spray rate of 10 mg
min1, and process a solution of danazol in IPA without and with
PVP, respectively. In both cases, we yield particles ranging from
approximately 1 mm to 5 mm, which are substantially larger than
the danazol particles formed with our microfluidic spray dryer.
Moreover, the degree of crystallinity of the resultant danazol
particles without PVP is high, as shown in Fig. 7A. We assume
that the smaller drop and particle size using our microfluidic
spray dryer is achieved due to the well-controllable flow condi-
tions in the microfluidic device and the use of pulsation-free
syringe pumps, which enable a degree of control over the spray
formation and mixing prior to the nozzle that cannot be achieved
in conventional macro-sized setups and eventually leads to the
formation of particles below 100 nm, as we have observed in our
studies.
However, the development of laboratory spray dryers towards
benchmarking the minimal particle size is an ongoing process,
though, and we expect novel equipment such as the Buechi B-90
to fabricate particles with submicron-size using our formula-
tions. However, with the intended use for early drug formulation
development, our spray drying approach exhibits several
advantages, which cannot be realized in a common spray dryer.
The dead volume of our chip is extremely small, thus avoiding
waste of the sample and facilitating experiments with minimal
sample volume. Furthermore, chip design and fabrication is easy2366 | Lab Chip, 2011, 11, 2362–2368and extremely flexible in terms of geometry, thereby allowing
customized design. As drugs in their early development stage
lack a complete toxicological profile, handling and cleaning of
contaminated equipment has to be performed with high safety
precautions. As the fabrication of our chip is inexpensive and
easy, it can just be discarded after use. An additional advantage
of our chip is sample collection. Due to the flexible setup the
particles can directly be collected in vials or on sample holders for
further characterization, thus avoiding waste and alteration of
sample properties.Experimental
Device fabrication
The PDMS microfluidic devices are fabricated using soft
lithography.27 All channels have a fixed height of 100 mm. The
PDMS replica is bonded to a flat sheet of cured PDMS using
oxygen plasma treatment. The plasma treatment renders the
microchannels temporarily hydrophilic.33 To retain the hydro-
philic surface modification, suitable for handling hydrophobic
drugs, the device is flushed with deionized water. The nozzle of
the spray dryer is prepared by slicing the outlet channel of the
stamped device with a razor blade. To achieve reproducible
accuracy when slicing, we include a guide to the eye in the initial
AutoCAD design of the spray dryer.Spray drying experiments
PVP (weight-averaged molecular weight, MW 10 000 g mol
1)
and all other chemicals are obtained from Sigma-Aldrich Co.
unless noted otherwise. Danazol (99.9%) is obtained from
Selectchemie AG. Water with a resistivity of 16.8 MU cm1 is
prepared using a Millipore Milli-Q system. All solutions are
filtered through a 0.2 mm PTFE filter (Millipore). We form
danazol nanoparticles using our microfluidic spray dryer.
To demonstrate long term stability of the process, each experi-
ment is performed over a time period of 2 h. We inject a saturatedThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlinesolution of danazol in IPA into the first inlet and water or IPA
into the second inlet at 5 mL h1 and 50 mL h1, respectively. For
the formation of co-precipitates, we inject PVP in water (1.5% w/
w) at 50 mL h1 into the second inlet. We fill the PE tubing that
connects the syringe pumps with the device with pure IPA to
prevent precipitation of the drug in the event of back flow of the
drug-loaded solvent stream into the second solvent reservoir, and
vice versa. To form the spray, air is injected into the third inlet at
2.09 bar. The spray is ejected into air and dried at room
temperature. We image the spray using a Phantom v9.1 camera
(Vision Research) at 64 000 fps. The droplet size is obtained by
measuring the size of at least 200 drops from high-speed camera
images.Product collection and characterization
Processed danazol is collected at distances between 5 cm and
30 cm from the spray nozzle. For SEM analysis, the spray is
collected on glass slides and coated with Pd/Pt. We use an
Ultra55 Field Emission SEM (Zeiss). The size distribution of the
nanoparticles is determined by image analysis of SEM photo-
graphs using a public domain, Java-based image processing
program, ImageJ. For XRD analysis and long-term experiments,
samples are collected in an aluminum box over which the spray
dryer is mounted. Due to the full-cone spray pattern, the dried
product assembles in a circular pattern solely on the bottom of
the collection box from which it is recovered in 70% to 95% yield.
XRD analysis is performed using a Scintag XDS2000 powder
diffractometer (Scintag, Cupertino, California, USA) with
Cu-Ka radiation at 40 kV and 30 mA. The XRD patterns are
taken at room temperature in the range of 10 # 2q # 50 with
a scan rate of 1 min1 and a step size of 0.02.Conclusions
Our microfluidic spray dryer is a versatile novel tool for early
formulation development of new drug candidates. Precisely
controlled generation of amorphous drug nanoparticles can
successfully be realized requiring only small quantities of sample.
The particles exhibit narrow size distribution and low mean
particle sizes. By independent injection of two solvent streams,
drug co-precipitates can be prepared as well. Our approach
should also be useful for forming composite nanoparticles with
freely tunable composition. As the spray is dried at room
temperature, our microfluidic device also enables processing of
thermally degradable materials. In addition, nanosuspensions,
which can greatly enhance the dissolution rate and bioavail-
ability of hydrophobic drugs, can be easily prepared by spraying
the nanoparticles into a stabilizer solution. Therefore, our
approach not only enables the formation of nanoprecipitates
with a small particle size, but also improves the versatility of
spray drying for manipulating the composition of the resultant
nanoparticles. Design and fabrication of spray drying devices is
easy and inexpensive, thereby allowing customized design for
each formulation and disposal of the whole chip after use. As
drug candidates during their early development phase lack
a complete toxicological profile, this aspect is more than valuable
contributing to safety and protection during development of new
pharmaceuticals.This journal is ª The Royal Society of Chemistry 2011Acknowledgements
We thank Christian Holtze and Jim Wilking for helpful discus-
sions and COMSOL AB for technical support. This work was
supported by BASF, the NSF (DMR-0602684), the Harvard
MRSEC (DMR-0820484), and the Massachusetts Life Sciences
Center. Experiments were performed in part at the Center for
Nanoscale Systems (CNS), which is supported by the NSF (ECS-
0335765). JT received funding from the Fund of the Chemical
Industry (Germany) and MW was funded by the German
Academic Exchange Service.Notes and references
1 J. A. Masi, R. W. Hansen and H. G. Grabowski, J. Health Econ.,
2003, 22, 151–185.
2 I. Kola and J. Landis, Nat. Rev. Drug Discovery, 2004, 3, 711–715.
3 H. Kubinyi, Nat. Rev. Drug Discovery, 2003, 2, 665–668.
4 X. Q. Chen, M. D. Autnan, C. Gesenberg and O. S. Gudmundsson,
AAPS PharmSciTech, 2006, 8, E402–208.
5 X. Chen, J. M. Vaughn, M. J. Yacaman, R. O. Williams III and
K. P. Johnston, J. Pharm. Sci., 2004, 93, 1867–1878.
6 B. E. Rabinow, Nat. Rev. Drug Discovery, 2004, 3, 785–796.
7 T. Panagiotou, S. V. Mesite and R. J. Fisher, Ind. Eng. Chem. Res.,
2009, 48, 1761–1771.
8 A. Schuffenhauer, N. Brown, P. Selzer, P. Ertl and E. Jacoby,
J. Chem. Inf. Model., 2006, 46, 525–535.
9 S. Venkatesh and R. A. Lipper, J. Pharm. Sci., 2000, 89, 145–154.
10 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Adv.
Drug Delivery Rev., 1997, 23, 3–25.
11 L. F. Huang andW. Q. Tony,Adv. Drug Delivery Rev., 2004, 56, 321–
334.
12 P. Costa and J. M. S. Lobo, Eur. J. Pharm. Sci., 2001, 13, 123–133.
13 L. Gao, D. Zhang andM. Chen, J. Nanopart. Res., 2008, 10, 845–862.
14 E. Merisko-Liversidge, G. G. Liversidge and E. R. Cooper, Eur. J.
Pharm. Sci., 2003, 18, 113–120.
15 F. Kesisoglou, S. Panmai and Y. Wu, Adv. Drug Delivery Rev., 2007,
59, 631–644.
16 R. Vehring, Pharm. Res., 2008, 25, 999–1022.
17 D. Chiou, T. A. G. Langrish and R. Braham, J. Food Eng., 2008, 86,
288–293.
18 Y. Gonnisson, S. I. Goncalves, J. P. Remon and C. Vervaet, Drug
Dev. Ind. Pharm., 2008, 34, 248–257.
19 A. Paudel, J. Van Humbeeck and G. Van den Mooter, Mol.
Pharmaceutics, 2010, 7, 113–1148.
20 H. Gao, W. Shi and L. B. Freund, Proc. Natl. Acad. Sci. U. S. A.,
2005, 102, 9469–9474.
21 X. Li, N. Anton, C. Arpagaus, F. Belleteix and T. F. Vandamme,
J. Controlled Release, 2010, DOI: 10.1016/j.jconrel.2010.07.113.
22 H. S. M. Ali, P. York and N. Blagden, Int. J. Pharm., 2009, 375, 107–
113.
23 H. Zhao, J.-X. Wang, Q.-A. Wang, J.-F. Chen and J. Yun, Ind. Eng.
Chem. Res., 2007, 46, 8229–8235.
24 G. Tetradis-Meris, D. Rossetti, C. P. de Torres, R. Cao, G. Lian and
R. Janes, Ind. Eng. Chem. Res., 2009, 48, 8881–8889.
25 P. W.Miller, L. E. Jennings, A. J. deMello, A. D. Gee, N. J. Long and
R. Vilar, Adv. Synth. Catal., 2009, 351, 3260–3268.
26 A. S. Utada, E. Lorenceau, D. R. Link, P. D. Kaplan, H. A. Stone
and D. A. Weitz, Science, 2005, 308, 537–541.
27 Y. Xia and G. M. Whitesides, Angew. Chem., Int. Ed., 1998, 37, 550–
575.
28 S. L. Peterson, A.McDonald, P. L. Gourley andD. Y. Sasaki, Journal
of Biomedical Materials Research Part A, 2004, 72A, 10–18.
29 D. B.Weibel and G.M.Whitesides,Curr. Opin. Chem. Biol., 2006, 10,
584–591.
30 T. Ozeki, S. Beppu, T. Mizoe, Y. Takashima, H. Yuasa and
H. Okada, Pharm. Res., 2006, 23, 177–183.
31 P.Mayer, W. H. J. Vaes and J. L. M. Hermens,Anal. Chem., 2000, 72,
459–464.
32 M. Honest, H. K. Jin, L. Kwanseop, P. Nokyoung and H. H. Jong,
Electrophoresis, 2003, 24, 3607–3619.Lab Chip, 2011, 11, 2362–2368 | 2367
Pu
bl
ish
ed
 o
n 
26
 M
ay
 2
01
1.
 D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TA
T 
BA
Y
RE
U
TH
 o
n 
8/
25
/2
02
0 
11
:3
5:
39
 A
M
. 
View Article Online33 B. Kim, E. T. K. Peterson, I. Papautsky, Proceedings of the 26th
Annual International Conference of the IEEE EMBS, San Francisco,
2004, 5013–5016.
34 P. Mao and J. Han, Lab Chip, 2009, 9, 586–591.
35 J. K. Deuschle, G. Buerki, H. M. Deuschle, S. Enders, J. Michler and
E. Arzt, Acta Mater., 2008, 56, 4390–4401.
36 D. Armani, C. Liu, N. Aluru, 12th Int. Conf. IEEE MEMS, 1999,
222–227.
37 A. S. Utada, L.-Y. Chu, A. Fernandez-Nieves, D. R. Link, C. Holtze
and D. A. Weitz, MRS Bull., 2007, 32, 702–708.
38 J.-Y. Zhang, Z.-G. Shen, J. Zhong, T.-T. Hu, J.-F. Chen, Z.-Q. Ma
and J. Yun, Int. J. Pharm., 2006, 323, 153–160.2368 | Lab Chip, 2011, 11, 2362–236839 S. D. Skapin and E. Matijevic, J. Colloid Interface Sci., 2004, 272, 90–
98.
40 S.M.Wong, I. W. Kellaway and S.Murdan, Int. J. Pharm., 2006, 317,
61–68.
41 H. Sekikawa, M. Nakano and T. Arita, Chemical and Pharmaceutical
Bulletin, 1978, 26, 118–126.
42 M. Yoshioka, B. C. Hancock and G. Zografi, J. Pharm. Sci., 1995, 84,
983–986.
43 L. S. Taylor and G. Zografi, Pharm. Res., 1997, 14, 1691–
1698.
44 J.-H. Kim and H.-K. Choi, International Journal of Pharmaceutics,
2002, 236, 81–85.This journal is ª The Royal Society of Chemistry 2011
